ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for IMC-002, a bispecific antibody (BsAb) targeting CD47 and CD20 for the treatment of systemic lupus erythematosus (SLE).
IMC-002 is designed to enhance antibody dependent cell phagocytosis (ADCP) and antibody dependent cytotoxicity (ADCC), simultaneously binding to CD47 and CD20 expressed on malignant B cells. The BsAb exhibits a higher affinity for CD20 compared to CD47, which is expected to improve therapeutic efficacy.
Systemic lupus erythematosus, a systemic autoimmune connective tissue disease characterized by immune inflammation, affects approximately 1.03 million people in China. It is more prevalent among middle-aged and young women aged 15-45, with a male to female ratio of 1:10-12. In vitro experiments have demonstrated that IMC-002 has a significantly stronger killing effect on B cells than rituximab. At a concentration of 1ug/ml, IMC-002 can significantly deplete CD19+B cells in the peripheral blood of SLE patients, indicating its potential for effective treatment of B cell-related autoimmune diseases.- Flcube.com
